NANOBIOTIX (NANO) Provides Business Update, Report FY21 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
March 30, 2022 4:21 PM EDTNew data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data with minimum follow-up of one year for full study population anticipated in mid-2023 Pivotal Phase III study, NANORAY-312, now actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across multiple European sites with US site activation anticipated in mid-2022 Expansion Phase to be added to Study 1100 evaluating NBTXR3 in combination with anti-PD-1 therapy in three cohorts, including two cohorts focused on R/M HNSCC patients... More
